PDCD1 and hepatocellular carcinoma: Of note, previous studies (42, 43) evaluating the combination of TACE, lenvatinib and PD-1 inhibitors in patients with unresectable HCC reported PFS of 11.4-13.3 months and OS of 23.6-24.0 months, which appeared to be much longer than the patients treated with TLP in our study.